Dysfunction of dopamine homeostasis: Clues in the hunt for novel Parkinson's disease therapies

FASEB Journal

Volumn 27, Issue 6, 2013, Pages 2101-2110

  Bisaglia, Marco ^a   Greggio, Elisa ^a   Beltramini, Mariano ^a   Bubacco, Luigi ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Dopamine metabolism; Dopaminergic pathways; Neurotransmission; Oxidative stress

Indexed keywords

APOMORPHINE; DOPAMINE; ENTACAPONE; LENTIVIRUS VECTOR; LEVODOPA; PRAMIPEXOLE; RASAGILINE; SELEGILINE; TOLCAPONE; VESICULAR MONOAMINE TRANSPORTER 2;

ADJUVANT THERAPY; CELL COMMUNICATION; CELL METABOLISM; CELL SUBPOPULATION; DISEASE COURSE; DOPAMINE METABOLISM; DRUG BIOAVAILABILITY; ENVIRONMENTAL FACTOR; HUMAN; HYPOTENSION; LIVER TOXICITY; MENTAL DISEASE; MESENCEPHALON; MESOLIMBIC DOPAMINERGIC SYSTEM; NAUSEA; NERVE CELL NECROSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; QUALITY OF LIFE; REVIEW; SYNAPTIC TRANSMISSION; TUBEROHYPOPHYSEAL TRACT;

DOPAMINE METABOLISM; DOPAMINERGIC PATHWAYS; NEUROTRANSMISSION; OXIDATIVE STRESS;

ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOPAMINE; DRUG DISCOVERY; HOMEOSTASIS; HUMANS; PARKINSON DISEASE;

EID: 84878758581     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-226852     Document Type: Review

References (93)

1. Chinta, S. J., and Andersen, J. K. (2005) Dopaminergic neurons. Int. J. Biochem. Cell Biol. 37, 942-9466
2. Rajput, A. H., Fenton, M. E., Birdi, S., Macaulay, R., George, D., Rozdilsky, B., Ang, L. C., Senthilselvan, A., and Hornykiewicz, O. (2002) Clinical-pathological study of levodopa complications. Mov. Disord. 17, 289-2966
3. Alam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C., Jenner, P., and Halliwell, B. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326-13299
4. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., and Mizuno, Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 93, 2696-27011
5. Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., and Halliwell, B. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196-12033
6. Pogson, J. H., Ivatt, R. M., and Whitworth, A. J. (2011) Molecular mechanisms of PINK1-related neurodegeneration. Curr. Neurol. Neurosci. Rep. 11, 283-2900
7. Cookson, M. R. Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. Cold Spring Harb. Perspect. Med. 2, a009415, 20122
8. Graham, D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-6433
9. Kuhn, D. M., Arthur, R. E., Jr., Thomas, D. M., and Elferink, L. A. (1999) Tyrosine hydroxylase is inactivated by catecholquinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 73, 1309-13177
10. LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., and Selkoe, D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214-12211
11. Bisaglia, M., Mammi, S., and Bubacco, L. (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J. Biol. Chem. 282, 15597-156055
12. Bisaglia, M., Tosatto, L., Munari, F., Tessari, I., de Laureto, P. P., Mammi, S., and Bubacco, L. (2010) Dopamine quinones interact with alpha-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 394, 424-4288
13. Girotto, S., Sturlese, M., Bellanda, M., Tessari, I., Cappellini, R., Bisaglia, M., Bubacco, L., and Mammi, S. (2012) Dopaminederived quinones affect the structure of the redox sensor DJ-1 through modifications at Cys-106 and Cys-53. J. Biol. Chem. 287, 18738-187499
14. Belluzzi, E., Bisaglia, M., Lazzarini, E., Tabares, L. C., Beltramini, M., and Bubacco, L. (2012) Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease. PLoS One 7, e380266
15. Kappock, T. J., and Caradonna, J. P. (1996) Pterin-dependent amino acid hydroxylases. Chem. Rev. 96, 2659-27566
16. Bowling, K. M., Huang, Z., Xu, D., Ferdousy, F., Funderburk, C. D., Karnik, N., Neckameyer, W., and O'Donnell, J. M. (2008) Direct binding of GTP cyclohydrolase and tyrosine hydroxylase: regulatory interactions between key enzymes in dopamine biosynthesis. J. Biol. Chem. 283, 31449-314599
17. Furukawa, Y., Graf, W. D., Wong, H., Shimadzu, M., and Kish, S. J. (2001) Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 56, 260-2633
18. Ludecke, B., Knappskog, P. M., Clayton, P. T., Surtees, R. A., Clelland, J. D., Heales, S. J., Brand, M. P., Bartholome, K., and Flatmark, T. (1996) Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum. Mol. Genet. 5, 1023-10288
19. Nagatsu, T., and Ichinose, H. (1997) GTP cyclohydrolase I gene, dystonia, juvenile parkinsonism, and Parkinson's disease. J. Neural Transm. Suppl. 49, 203-2099
20. Bademci, G., Edwards, T. L., Torres, A. L., Scott, W. K., Zuchner, S., Martin, E. R., Vance, J. M., and Wang, L. (2010) A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease. Hum. Mutat. 31, E1767-17711
21. Ichinose, H., Ohye, T., Fujita, K., Pantucek, F., Lange, K., Riederer, P., and Nagatsu, T. (1994) Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J. Neural. Transm. Park. Dis. Dement. Sect. 8, 149-1588
22. Haavik, J., Almas, B., and Flatmark, T. (1997) Generation of reactive oxygen species by tyrosine hydroxylase: a possible contribution to the degeneration of dopaminergic neurons? J. Neurochem. 68, 328-3322
23. Choi, H. J., Lee, S. Y., Cho, Y., No, H., Kim, S. W., and Hwang, O. (2006) Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson's disease. Neurochem. Int. 48, 255-2622
24. De La Cruz, C. P., Revilla, E., Venero, J. L., Ayala, A., Cano, J., and Machado, A. (1996) Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rat. Free Radic. Biol. Med. 20, 53-611
25. Ara, J., Przedborski, S., Naini, A. B., Jackson-Lewis, V., Trifiletti, R. R., Horwitz, J., and Ischiropoulos, H. (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl. Acad. Sci. U. S. A. 95, 7659-76633
26. Xu, Y., Stokes, A. H., Roskoski, R., Jr., and Vrana, K. E. (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J. Neurosci. Res. 54, 691-6977
27. Mandel, R. J., Burger, C., and Snyder, R. O. (2008) Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. Exp. Neurol. 209, 58-711
28. Feng, L. R., and Maguire-Zeiss, K. A. (2010) Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs 24, 177-1922
29. Mandel, R. J., Rendahl, K. G., Spratt, S. K., Snyder, R. O., Cohen, L. K., and Leff, S. E. (1998) Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J. Neurosci. 18, 4271-42844
30. Daadi, M. M., Pivirotto, P., Bringas, J., Cunningham, J., Forsayeth, J., Eberling, J., and Bankiewicz, K. S. (2006) Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. Neuroreport 17, 201-2044
31. Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W., Reutter, B., and Cunningham, J. (2006) Longterm clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 14, 564-5700
32. Dauer, W., and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-9099
33. Fan, D. S., Ogawa, M., Fujimoto, K. I., Ikeguchi, K., Ogasawara, Y., Urabe, M., Nishizawa, M., Nakano, I., Yoshida, M., Nagatsu, I., Ichinose, H., Nagatsu, T., Kurtzman, G. J., and Ozawa, K. (1998) Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. 9, 2527-25355
34. Shen, Y., Muramatsu, S. I., Ikeguchi, K., Fujimoto, K. I., Fan, D. S., Ogawa, M., Mizukami, H., Urabe, M., Kume, A., Nagatsu, I., Urano, F., Suzuki, T., Ichinose, H., Nagatsu, T., Monahan, J., Nakano, I., and Ozawa, K. (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther. 11, 1509-15199
35. Jarraya, B., Boulet, S., Ralph, G. S., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., Herard, A. S., Day, D. M., Brouillet, E., Kingsman, S. M., Hantraye, P., Mitrophanous, K. A., Mazarakis, N. D., and Palfi, S. (2009) Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med. 1, 2ra44
36. Eiden, L. E., Schafer, M. K., Weihe, E., and Schutz, B. (2004) The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflügers Arch. 447, 636-6400
37. Glatt, C. E., Wahner, A. D., White, D. J., Ruiz-Linares, A., and Ritz, B. (2006) Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum. Mol. Genet. 15, 299-3055
38. Caudle, W. M., Colebrooke, R. E., Emson, P. C., and Miller, G. W. (2008) Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci. 31, 303-3088
39. Carlsson, A., Lindqvist, M., and Magnusson, T. (1957) 3,4- Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180, 12000
40. Colpaert, F. C. (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26, 1431-14400
41. Choi, H. J., Lee, S. Y., Cho, Y., and Hwang, O. (2005) Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. Neurochem. Int. 46, 329-3355
42. Sulzer, D. (2011) How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69, 628-6499
43. Vergo, S., Johansen, J. L., Leist, M., and Lotharius, J. (2007) Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res. 1185, 18-322
44. Near, J. A. (1986) [3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol. Pharmacol. 30, 252-257
45. (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66, 366-3722
46. Kenney, C., and Jankovic, J. (2006) Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev. Neurother. 6, 7-177
47. Jankovic, J., and Clarence-Smith, K. (2011) Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev. Neurother. 11, 1509-15233
48. Fumagalli, F., Gainetdinov, R. R., Wang, Y. M., Valenzano, K. J., Miller, G. W., and Caron, M. G. (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19, 2424-24311
49. Wang, Y. M., Gainetdinov, R. R., Fumagalli, F., Xu, F., Jones, S. R., Bock, C. B., Miller, G. W., Wightman, R. M., and Caron, M. G. (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285-12966
50. Mooslehner, K. A., Chan, P. M., Xu, W., Liu, L., Smadja, C., Humby, T., Allen, N. D., Wilkinson, L. S., and Emson, P. C. (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol. Cell. Biol. 21, 5321-53311
51. Caudle, W. M., Richardson, J. R., Wang, M. Z., Taylor, T. N., Guillot, T. S., McCormack, A. L., Colebrooke, R. E., Di Monte, D. A., Emson, P. C., and Miller, G. W. (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 8138-81488
52. Truong, J. G., Hanson, G. R., and Fleckenstein, A. E. (2004) Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration. Eur. J. Pharmacol. 492, 143-1477
53. Truong, J. G., Rau, K. S., Hanson, G. R., and Fleckenstein, A. E. (2003) Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. Eur. J. Pharmacol. 474, 223-2266
54. McElvain, J. S., and Schenk, J. O. (1992) A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem. Pharmacol. 43, 2189-21999
55. Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I. (1983) Chronic Parkinsonism in humans due to a product of meperidine- analog synthesis. Science 219, 979-9800
56. Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., and Snyder, S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4- phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 82, 2173-21777
57. Przedborski, S., Jackson-Lewis, V., Djaldetti, R., Liberatore, G., Vila, M., Vukosavic, S., and Almer, G. (2000) The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16, 135-1422
58. Elbaz, A., and Tranchant, C. (2007) Epidemiologic studies of environmental exposures in Parkinson's disease. J. Neurol. Sci. 262, 37-444
59. Yang, W., and Tiffany-Castiglioni, E. (2005) The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis. J. Toxicol. Environ. Health A 68, 1939-19611
60. Richardson, J. R., Quan, Y., Sherer, T. B., Greenamyre, J. T., and Miller, G. W. (2005) Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol. Sci. 88, 193-2011
61. Afonso-Oramas, D., Cruz-Muros, I., Alvarez de la Rosa, D., Abreu, P., Giraldez, T., Castro-Hernandez, J., Salas-Hernandez, J., Lanciego, J. L., Rodriguez, M., and Gonzalez-Hernandez, T. (2009) Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol. Dis. 36, 494-5088
62. Uhl, G. R., Walther, D., Mash, D., Faucheux, B., and Javoy-Agid, F. (1994) Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann. Neurol. 35, 494-4988
63. Fumagalli, F., Gainetdinov, R. R., Valenzano, K. J., and Caron, M. G. (1998) Role of dopamine transporter in methamphetamine- induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18, 4861-48699
64. Kelada, S. N., Checkoway, H., Kardia, S. L., Carlson, C. S., Costa-Mallen, P., Eaton, D. L., Firestone, J., Powers, K. M., Swanson, P. D., Franklin, G. M., Longstreth, W. T., Jr., Weller, T. S., Afsharinejad, Z., and Costa, L. G. (2006) 5= and 3= region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study. Hum. Mol. Genet. 15, 3055-30622
65. Ritz, B. R., Manthripragada, A. D., Costello, S., Lincoln, S. J., Farrer, M. J., Cockburn, M., and Bronstein, J. (2009) Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ. Health Perspect. 117, 964-9699
66. Varrone, A., and Halldin, C. (2012) New developments of dopaminergic imaging in Parkinson's disease. Q. J. Nucl. Med. Mol. Imaging 56, 68-822
67. Calne, D. B., Karoum, F., Ruthven, C. R., and Sandler, M. (1969) The metabolism of orally administered L-Dopa in Parkinsonism. Br. J. Pharmacol. 37, 57-688
68. Bonifacio, M. J., Palma, P. N., Almeida, L., and Soares-da-Silva, P. (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev. 13, 352-3799
69. Bartholini, G., Burkard, W. P., and Pletscher, A. (1967) Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215, 852-8533
70. Lundstrom, K., Salminen, M., Jalanko, A., Savolainen, R., and Ulmanen, I. (1991) Cloning and characterization of human placental catechol-O- methyltransferase cDNA. DNA Cell Biol. 10, 181-1899
71. Tenhunen, J., Salminen, M., Lundstrom, K., Kiviluoto, T., Savolainen, R., and Ulmanen, I. (1994) Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem. 223, 1049-10599
72. Meyer-Lindenberg, A., Kohn, P. D., Kolachana, B., Kippenhan, S., McInerney-Leo, A., Nussbaum, R., Weinberger, D. R., and Berman, K. F. (2005) Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 8, 594-5966
73. Kaplan, G. P., Hartman, B. K., and Creveling, C. R. (1979) Immunohistochemical demonstration of catechol-o-methyltransferase in mammalian brain. Brain Res. 167, 241-2500
74. Eisenhofer, G., Kopin, I. J., and Goldstein, D. S. (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56, 331-3499
75. Shih, J. C., Chen, K., and Ridd, M. J. (1999) Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22, 197-2177
76. Youdim, M. B., Edmondson, D., and Tipton, K. F. (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7, 295-3099
77. Levitt, P., Pintar, J. E., and Breakefield, X. O. (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. U. S. A. 79, 6385-63899
78. Westlund, K. N., Denney, R. M., Kochersperger, L. M., Rose, R. M., and Abell, C. W. (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230, 181-1833
79. Senthil, K., Aranganathan, S., and Nalini, N. (2004) Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin. Chim. Acta 339, 27-322
80. Da Prada, M., Zurcher, G., Wuthrich, I., and Haefely, W. E. (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural. Transm. Suppl. 26, 31-566
81. Riederer, P., and Laux, G. (2011) MAO-inhibitors in Parkinson's disease. Exp. Neurobiol. 20, 1-177
82. Birkmayer, W., Riederer, P., Ambrozi, L., and Youdim, M. B. (1977) Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1, 439-4433
83. Hauser, R. A. (2009) New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Parkinsonism Relat. Disord. 15(Suppl. 3), S17-S211
84. Jankovic, J., and Poewe, W. (2012) Therapies in Parkinson's disease. Curr. Opin. Neurol. 25, 433-4477
85. Marchitti, S. A., Deitrich, R. A., and Vasiliou, V. (2007) Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev. 59, 125-1500
86. Jinsmaa, Y., Florang, V. R., Rees, J. N., Mexas, L. M., Eckert, L. L., Allen, E. M., Anderson, D. G., and Doorn, J. A. (2011) Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. Chem. Biol. Interact. 192, 118-1211
87. Goldstein, D. S., Sullivan, P., Holmes, C., Kopin, I. J., Basile, M. J., and Mash, D. C. (2011) Catechols in post-mortem brain of patients with Parkinson disease. Eur. J. Neurol. 18, 703-7100
88. Vasiliou, V., and Nebert, D. W. (2005) Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum. Genomics 2, 138-1433
89. Pietruszko, R., Meier, J., Major, L. F., Saini, N., Manz, H., and Hawley, R. J. (1984) Human brain: aldehyde dehydrogenase activity and isozyme distribution in different areas. Alcohol 1, 363-3677
90. Galter, D., Buervenich, S., Carmine, A., Anvret, M., and Olson, L. (2003) ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. Neurobiol. Dis. 14, 637-6477
91. Anderson, D. W., Schray, R. C., Duester, G., and Schneider, J. S. (2011) Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system. Brain Res. 1408, 81-877
92. Wey, M. C., Fernandez, E., Martinez, P. A., Sullivan, P., Goldstein, D. S., and Strong, R. (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One 7, e315222
93. Kotraiah, V., Pallares, D., Toema, D., Kong, D., and Beausoleil, E. (2012) Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening. [E-pub ahead of print] J. Enzyme Inhib. Med. Chem. doi: 10.3109/14756366.2011.6533533